Recommendations for the Management of Children With H1N1 Novel Influenza Infection
Journal
Pediatrics and Neonatology
Journal Volume
51
Journal Issue
1
Pages
1-4
Date Issued
2010
Author(s)
Lin T.-Y.
Hsieh K.-S.
Shyur S.-D.
Hsia S.-H.
Huang Y.-F.
Hwang B.
Chiu N.-C.
Chi C.-S.
Chen P.-Y.
Huang Y.-C.
Lee C.-Y.
Abstract
As a member of orthomyxoviridae family, influenza viruses are enveloped viruses containing eight RNA segments. The main antigenic determinants of influenza A and B viruses are two surface glycoproteins, the hemagglutinin (H) and the neuraminidase (N). A genetic reassortment between influenza A viruses from different animal hosts may lead to an antigenic shift and thereby increase the risk of a potential pandemic. H1N1 and H3N2 subtypes of influenza A have been circulating all over the world as seasonal influenza since the last H3N2 pandemic in 1968.1 In April 2009, the Centers for Disease Control and Prevention of the United States identified two cases of human infection with the H1N1 novel influenza virus. The greatest initial burden of critical illness and deaths occurred in Mexico between March and June 2009. The virus is a triple-reassortant containing gene segments from swine influenza virus, human influenza virus, and avian influenza virus. Genes for hemagglutinin and neuraminidase come from swine influenza virus.2 On June 11th, 2009, the World Health Organization raised the level of influenza A (H1N1) pandemic alert from phase 5 to 6, as sustained communitylevel transmission of the virus is taking place in more than one region of the world. Recommendations for the Management of Children With H1N1 Novel Influenza Infection
SDGs
Other Subjects
creatine kinase; immunoglobulin; influenza vaccine; Influenza virus hemagglutinin; oseltamivir; sialidase inhibitor; steroid; virus sialidase; zanamivir; active immunization; antiviral resistance; antiviral therapy; article; avian influenza; bacterial infection; breathing rate; child; child hospitalization; clinical feature; developmental disorder; diarrhea; digestive system function disorder; disease transmission; drug contraindication; drug fever; drug indication; drug megadose; egg allergy; encephalitis; genetic reassortment; human; infection control; influenza; Influenza virus A H1N1; injection site erythema; injection site pain; injection site swelling; laboratory diagnosis; lung complication; lymphocytopenia; mixed infection; neurological complication; oxygenation; pediatrics; personal hygiene; pneumonia; recommended drug dose; reverse transcription polymerase chain reaction; risk factor; screening test; sputum analysis; Staphylococcus aureus; Streptococcus pneumoniae; swine influenza virus; symptom; treatment duration; virus culture; virus shedding; vomiting; Humans; Immunization; Infant; Infant, Newborn; Influenza A Virus, H1N1 Subtype; Influenza Vaccines; Influenza, Human; Risk Factors
Type
journal article